-
公开(公告)号：CA2544369C
公开(公告)日：2014-08-05
申请号：CA2544369
申请日：2004-06-18
Applicant: ACADEMIA SINICA
Inventor： CHEN YUAN-TSONG , HUNG SHUEN-IU , CHUNG WEN-HUNG , WU JER-YUARN
Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug hypersensitivity syndrome (HSS). It was discovered that an HLA-13 allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-13*1502 allele. In addition, another HLA-13 allele, HLA-B*5801, is particularly associated with SJS/TEN or HSS induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-13*4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between the DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.
-
公开(公告)号：AU2011240814B2
公开(公告)日：2014-07-17
申请号：AU2011240814
申请日：2011-04-11
Applicant: ACADEMIA SINICA
Inventor： CHEN YUAN-TSONG , HUNG SHUEN-LU , WEI CHUN-YU
Abstract: A method for identifying from an HLA library an HLA complex that specifically binds to a compound. This method can be relied on to assess whether a compound is likely to induce an adverse drug reaction and, if so, in which human population.
-
公开(公告)号：ES2422735T3
公开(公告)日：2013-09-13
申请号：ES07797432
申请日：2007-05-11
Applicant: ACADEMIA SINICA , PHARMIGENE INC
Inventor： CHEN YUAN-TSONG , HUNG SHUEN-LU , SHEN CHIH-LUNG , CHANG CHI-FENG , LIN HSIN-YU , CHEN WEI-HSUAN
IPC: C12Q1/68
Abstract: Un procedimiento para evaluar, en un paciente humano, el riesgo a desarrollar una reacción adversa a unmedicamento en respuesta a un fármaco, que comprende detectar la presencia de HLA-B*1502 en una muestra obtenida del paciente y correlacionar la presencia de HLA-B*1502 en la muestra con un riesgo aumentado de desarrollo de una reacciónadversa a un medicamento en el paciente en respuesta al fármaco, en el que la reacción adversa a un medicamentoes el síndrome de Stevens-Johnson o necrólisis epidérmica tóxica y el fármaco es oxcarbazepina o licarbazepina.
-
公开(公告)号：AU2011240814A1
公开(公告)日：2012-10-25
申请号：AU2011240814
申请日：2011-04-11
Applicant: ACADEMIA SINICA
Inventor： CHEN YUAN-TSONG , HUNG SHUEN-LU , WEI CHUN-YU
Abstract: A method for identifying from an HLA library an HLA complex that specifically binds to a compound. This method can be relied on to assess whether a compound is likely to induce an adverse drug reaction and, if so, in which human population.
-
公开(公告)号：BRPI0710436A2
公开(公告)日：2012-10-09
申请号：BRPI0710436
申请日：2007-05-11
Applicant: ACADEMIA SINICA , PHARMIGENE INC
Inventor： CHEN YUAN-TSONG , HUNG SHUEN-LU , SHEN CHIH-LUNG , LIN HSIN-YU , CHENN WEI-HSUAN , CHANG CHI-FENG
IPC: C12Q1/68
Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).
-
Patent Agency Ranking
公开(公告)号：CA2955214A1
公开(公告)日：2016-01-28
申请号：CA2955214
申请日：2015-07-23
Applicant: ACADEMIA SINICA , CHEN YUAN-TSONG
Inventor： CHEN YUAN-TSONG , WU JER-YUARN , KO TAI-MING , KUO HO-CHANG , CHANG JENG-SHENG
IPC: G01N33/53 , A61K39/395 , A61P9/00 , A61P29/00
Abstract: Described is a method of diagnosing, treating, or monitoring a treatment for Kawasaki disease in a subject. The method includes detecting the level of a biomarker in a sample obtained from the subject, the biomarker being IL-7F, sCD40L, MPIF-1, E-selectin, IP-10, or IL-33. The level is compared to a cut-off level. Also described is a kit for carrying out the method.
-
公开(公告)号：NZ597628A
公开(公告)日：2013-07-26
申请号：NZ59762807
申请日：2007-05-11
Applicant: ACADEMIA SINICA , PHARMIGENE INC
Inventor： CHEN YUAN-TSONG , HUNG SHUEN-LU , SHEN CHIH-LUNG , CHANG CHI-FENG , LIN HSIN-YU , CHEN WEI-HSUAN
IPC: C12Q1/68
Abstract: 597628 Disclosed is a method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising: Detecting the presence of HLA-B*5801 in a sample obtained from the patient; and Correlating the presence of HLA-B*5801 in the sample with an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is Stevens-Johnson syndrome or toxic epidermal necrolysis and the drug is oxypurinol.
-
公开(公告)号：NZ572259A
公开(公告)日：2012-03-30
申请号：NZ57225907
申请日：2007-05-11
Applicant: ACADEMIA SINICA , PHARMIGENE INC
Inventor： CHEN YUAN-TSONG , HUNG SHUEN-LU , SHEN CHIH-LUNG , CHANG CHI-FENG , LIN HSIN-YU , CHEN WEI-HSUAN
IPC: C12Q1/68
Abstract: Disclosed is a method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising detecting the presence of HLA-B*1502 in a sample obtained from the patient, and correlating the presence of HLA-B*1502 in the sample with an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is Stevens-Johnson syndrome or toxic epidermal necrolysis and the drug is oxcarbazepine.
-
公开(公告)号：PL1697539T3
公开(公告)日：2010-12-31
申请号：PL04776718
申请日：2004-06-18
Applicant: ACADEMIA SINICA
Inventor： CHEN YUAN-TSONG , HUNG SHUEN-IU , CHUNG WEN-HUNG , WU JER-YUARN
-
公开(公告)号：DE602004028508D1
公开(公告)日：2010-09-16
申请号：DE602004028508
申请日：2004-06-18
Applicant: ACADEMIA SINICA
Inventor： CHEN YUAN-TSONG , HUNG SHUEN-IU , CHUNG WEN-HUNG , WU JER-YUARN
-
-
-
-
-
-
-
-
-
Search Results
45
records
(took 0.017 seconds)
